Latus Bio has secured $97 million in Series A financing to push two experimental gene therapies toward the clinic, bringing the Philadelphia company's total raise to a figure that reflects both investor enthusiasm for precision brain-delivery platforms and the persistent challenges of treating neurological disease.
The round, led by 8VC with backing from DCVC Bio, BioAdvance, Ben Franklin Technology Partners, and several other investors including Korea Development Bank, closed on May 4, 2026. It represents an extension of an initial $54 million tranche that came together in mid-2024, according to the company. The additional capital arrives as Latus targets an IND submission for its Huntington's disease program in Q3 2026 and awaits data from an ongoing trial in a rare pediatric disorder known as Batten disease.
At the center of Latus' pitch is a technical problem that has bedeviled gene therapy developers for years: getting therapeutic payloads into the brain efficiently and safely. Standard adeno-associated virus vectors, the workhorses of gene therapy, often require high doses to achieve meaningful transduction in central nervous system tissue. That can trigger immune responses or dose-limiting toxicities, outcomes that have derailed more than one promising program in recent years.
Latus engineers custom AAV capsids designed to home in on specific brain cell types at lower doses. The technology emerged from the lab of Beverly L. Davidson at Children's Hospital of Philadelphia, where researchers screened millions of capsid variants in non-human primates to identify versions with superior delivery profiles. Two studies published in May 2025 in Science Translational Medicine and Nature Communications described tests of roughly 6.8 million capsid designs, with some engineered versions demonstrating higher brain transduction than commonly used serotypes.
Whether that preclinical promise translates to human patients remains an open question. The company's lead asset, LTS-101, targets CLN2 disease, a fatal pediatric lysosomal storage disorder affecting about one in 200,000 children. The FDA cleared an investigational new drug application in December and granted the program Fast Track, Orphan Drug and Rare Pediatric Disease designations. Latus has said it expects to initiate a first-in-human trial in Q3 2026, though as of October 2026, no trial initiation had been publicly announced.
The second program, LTS-201, takes aim at Huntington's disease using a different mechanism than most gene therapies in development for that indication. Rather than suppressing the mutant huntingtin gene directly, Latus delivers a microRNA targeting MSH3, a gene implicated in the somatic instability of the huntingtin mutation. The company plans to file an IND for that program in the coming months.
Huntington's represents a larger commercial opportunity than ultra-rare pediatric conditions, with more than 100,000 patients across major markets and no approved disease-modifying treatments. But the field has proven treacherous. UniQure's AMT-130, a direct huntingtin-lowering gene therapy, faced regulatory feedback suggesting its Phase I/II data would likely need bolstering before a biologics license application could proceed. That setback underscored the FDA's caution around irreversible genetic interventions for chronic neurodegenerative diseases.
"This financing supports the advancement of our clinical pipeline and strategy to expand gene therapy to larger diseases," CEO P. Peter Ghoroghchian said when the extension closed.
Latus has moved to beef up its leadership in recent months. In September 2026, Donald Hayden, who previously ran global pharmaceuticals at Bristol Myers Squibb and chaired REGENXBIO, joined as board chairman. Michael MacLean, former CFO at Avidity Biosciences, was appointed to the board in September 2026 and chairs the audit committee. In June, the company brought on Bethany Mancilla as chief business officer; Mancilla came from Capsida Biotherapeutics, where she reportedly secured more than $250 million in non-dilutive deals.
The company operates facilities in Philadelphia and Boston. Its employee count remains relatively modest, consistent with an early-stage biotech preparing for clinical proof-of-concept studies.
Latus competes in a crowded field of companies engineering next-generation capsids for CNS delivery. Voyager Therapeutics has developed TRACER capsids designed to cross the blood-brain barrier after intravenous administration. Capsida, Dyno Therapeutics and Affinia Therapeutics are also advancing proprietary capsid platforms. Each claims advantages in tissue tropism, manufacturing efficiency or immune evasion, though head-to-head comparisons remain scarce.
Francisco Gimenez, the 8VC partner who joined Latus' board, said the financing "reflects conviction in Latus' differentiated and scalable approaches to gene therapy." That conviction will soon face a more exacting test: whether the company's engineered capsids can deliver meaningful clinical benefit in patients whose treatment options have long been limited to symptomatic management, if that.
